The finding -- reported Nov. 4, 2012, at the American Heart Association's Scientific Sessions annual meeting and published in the Journal of the American Medical Association -- provides new insights into a subset of heart patients with acute coronary syndromes (ACS) whose risk for cardiovascular events remained unchanged despite taking medicine that successfully reduced platelet clotting function.
No comments:
Post a Comment